686 related articles for article (PubMed ID: 36198685)
21. Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non-Small Cell Lung Cancer.
Jeong Y; Hellyer JA; Stehr H; Hoang NT; Niu X; Das M; Padda SK; Ramchandran K; Neal JW; Wakelee H; Diehn M
Clin Cancer Res; 2020 Jan; 26(1):274-281. PubMed ID: 31548347
[TBL] [Abstract][Full Text] [Related]
22. Targeting angiogenesis in squamous non-small cell lung cancer.
Piperdi B; Merla A; Perez-Soler R
Drugs; 2014 Mar; 74(4):403-13. PubMed ID: 24578213
[TBL] [Abstract][Full Text] [Related]
23. Methylseleninic acid activates Keap1/Nrf2 pathway via up-regulating miR-200a in human oesophageal squamous cell carcinoma cells.
Liu M; Hu C; Xu Q; Chen L; Ma K; Xu N; Zhu H
Biosci Rep; 2015 Sep; 35(5):. PubMed ID: 26341629
[TBL] [Abstract][Full Text] [Related]
24. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
Beck JT; Ismail A; Tolomeo C
Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
[TBL] [Abstract][Full Text] [Related]
25. Ubiquitination-mediated molecular pathway alterations in human lung squamous cell carcinomas identified by quantitative ubiquitinomics.
Zhan X; Lu M; Yang L; Yang J; Zhan X; Zheng S; Guo Y; Li B; Wen S; Li J; Li N
Front Endocrinol (Lausanne); 2022; 13():970843. PubMed ID: 36187110
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of immunotherapies for advanced squamous non-small cell lung cancer: a systematic review.
Cheng M; Shao Y; Li L; Jiang M; Song Z
BMC Cancer; 2024 Mar; 24(1):312. PubMed ID: 38448878
[TBL] [Abstract][Full Text] [Related]
27. Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade.
Wu W; Onn A; Isobe T; Itasaka S; Langley RR; Shitani T; Shibuya K; Komaki R; Ryan AJ; Fidler IJ; Herbst RS; O'Reilly MS
Mol Cancer Ther; 2007 Feb; 6(2):471-83. PubMed ID: 17308046
[TBL] [Abstract][Full Text] [Related]
28. Second-line therapy of squamous non-small cell lung cancer: an evolving landscape.
Lazzari C; Karachaliou N; Gregorc V; Bulotta A; Gonzalez-Cao M; Verlicchi A; Altavilla G; Rosell R; Santarpia M
Expert Rev Respir Med; 2017 Jun; 11(6):469-479. PubMed ID: 28467720
[TBL] [Abstract][Full Text] [Related]
29. A proteogenomic portrait of lung squamous cell carcinoma.
Satpathy S; Krug K; Jean Beltran PM; Savage SR; Petralia F; Kumar-Sinha C; Dou Y; Reva B; Kane MH; Avanessian SC; Vasaikar SV; Krek A; Lei JT; Jaehnig EJ; Omelchenko T; Geffen Y; Bergstrom EJ; Stathias V; Christianson KE; Heiman DI; Cieslik MP; Cao S; Song X; Ji J; Liu W; Li K; Wen B; Li Y; Gümüş ZH; Selvan ME; Soundararajan R; Visal TH; Raso MG; Parra ER; Babur Ö; Vats P; Anand S; Schraink T; Cornwell M; Rodrigues FM; Zhu H; Mo CK; Zhang Y; da Veiga Leprevost F; Huang C; Chinnaiyan AM; Wyczalkowski MA; Omenn GS; Newton CJ; Schurer S; Ruggles KV; Fenyö D; Jewell SD; Thiagarajan M; Mesri M; Rodriguez H; Mani SA; Udeshi ND; Getz G; Suh J; Li QK; Hostetter G; Paik PK; Dhanasekaran SM; Govindan R; Ding L; Robles AI; Clauser KR; Nesvizhskii AI; Wang P; Carr SA; Zhang B; Mani DR; Gillette MA;
Cell; 2021 Aug; 184(16):4348-4371.e40. PubMed ID: 34358469
[TBL] [Abstract][Full Text] [Related]
30. Vascular endothelial growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-small cell lung cancer.
Barr MP; Gray SG; Gately K; Hams E; Fallon PG; Davies AM; Richard DJ; Pidgeon GP; O'Byrne KJ
Mol Cancer; 2015 Feb; 14():45. PubMed ID: 25889301
[TBL] [Abstract][Full Text] [Related]
31. Role of NRF2 in Lung Cancer.
Sánchez-Ortega M; Carrera AC; Garrido A
Cells; 2021 Jul; 10(8):. PubMed ID: 34440648
[TBL] [Abstract][Full Text] [Related]
32. KEAP1-Mutant NSCLC: The Catastrophic Failure of a Cell-Protecting Hub.
Scalera S; Mazzotta M; Cortile C; Krasniqi E; De Maria R; Cappuzzo F; Ciliberto G; Maugeri-Saccà M
J Thorac Oncol; 2022 Jun; 17(6):751-757. PubMed ID: 35351670
[TBL] [Abstract][Full Text] [Related]
33. KEAP1/NRF2 signaling pathway mutations in cervical cancer.
Chu XY; Li ZJ; Zheng ZW; Tao YL; Zou FX; Yang XF
Eur Rev Med Pharmacol Sci; 2018 Jul; 22(14):4458-4466. PubMed ID: 30058679
[TBL] [Abstract][Full Text] [Related]
34. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S
Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034
[TBL] [Abstract][Full Text] [Related]
35. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in
Galan-Cobo A; Sitthideatphaiboon P; Qu X; Poteete A; Pisegna MA; Tong P; Chen PH; Boroughs LK; Rodriguez MLM; Zhang W; Parlati F; Wang J; Gandhi V; Skoulidis F; DeBerardinis RJ; Minna JD; Heymach JV
Cancer Res; 2019 Jul; 79(13):3251-3267. PubMed ID: 31040157
[TBL] [Abstract][Full Text] [Related]
36. Modification of platinum sensitivity by KEAP1/NRF2 signals in non-small cell lung cancer.
Tian Y; Wu K; Liu Q; Han N; Zhang L; Chu Q; Chen Y
J Hematol Oncol; 2016 Sep; 9(1):83. PubMed ID: 27601007
[TBL] [Abstract][Full Text] [Related]
37. New Therapeutic Opportunities for the Treatment of Squamous Cell Carcinomas: A Focus on Novel Driver Kinases.
Bensen R; Brognard J
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799513
[TBL] [Abstract][Full Text] [Related]
38. Identification of pyroptosis-related long non-coding RNAs with prognosis and therapy in lung squamous cell carcinoma.
Zhang Y; Wang Y; Yin X; Huang Y
Sci Rep; 2022 Jul; 12(1):11206. PubMed ID: 35778526
[TBL] [Abstract][Full Text] [Related]
39. MicroRNA‑195 is associated with regulating the pathophysiologic process of human laryngeal squamous cell carcinoma.
Pang H; Xu X; Dai L; Wang K; Yao X
Mol Med Rep; 2018 Apr; 17(4):5283-5291. PubMed ID: 29393451
[TBL] [Abstract][Full Text] [Related]
40. Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy.
Drilon A; Rekhtman N; Ladanyi M; Paik P
Lancet Oncol; 2012 Oct; 13(10):e418-26. PubMed ID: 23026827
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
